Gout in the Foot: A Podiatrist’s Guide to Attacks, Diagnosis, and Long-Term Management

Medically reviewed by Dr. Tom Biernacki, DPM — Board-Certified Podiatric Surgeon — Balance Foot & Ankle, Howell & Bloomfield Hills, MI. Last updated April 2026.

▶ Watch

Gout is the most common inflammatory arthritis in adults — and the foot is the most common site of gout attacks. Despite being a highly treatable condition, gout remains dramatically undertreated, with many patients suffering repeated attacks for years before receiving appropriate urate-lowering therapy. The consequences of inadequately managed gout extend beyond acute pain: chronic tophaceous gout produces permanent joint destruction, tophi (uric acid crystal deposits) in soft tissue, and significant renal disease.

Why the Big Toe?

The first metatarsophalangeal (MTP) joint — the base of the big toe — is the most common site of acute gout, a presentation historically called podagra. The reasons are mechanistic: uric acid crystals (monosodium urate) form preferentially at lower temperatures, and the great toe joint is the coolest peripheral joint in the body. Urate also accumulates in cartilage with high proteoglycan content, and the first MTP joint has particularly high proteoglycan-rich articular cartilage.

Other common foot and ankle gout locations include the ankle joint itself, the midfoot (Lisfranc area), the heel, and the Achilles tendon bursa — any of which can mimic infection, ankle sprain, or other conditions.

Recognizing an Acute Gout Attack

The classic acute gout presentation develops rapidly — often awakening patients at night — with:

• Intense, severe joint pain rated 9–10/10 — even light touch or sheet contact is unbearable
• Dramatic joint swelling, erythema (redness), and warmth
• Onset at rest, often overnight
• Peak intensity within 12–24 hours
• Self-resolution within 7–14 days without treatment (but earlier resolution with treatment)

The critical diagnostic distinction is between gout and septic arthritis (joint infection) — both present with a hot, red, swollen joint with severe pain. Septic arthritis is a surgical emergency requiring joint aspiration and drainage; gout is managed medically. Any patient with a hot red joint who appears systemically unwell (fever, chills, elevated white cell count) requires urgent evaluation to exclude infection before assuming gout.

Diagnosis

Serum uric acid is an important but imperfect marker — levels may be normal or even low during an acute attack (uric acid redistributes into the joint during crystal shedding). The gold-standard diagnosis is joint aspiration with polarized microscopy identifying needle-shaped, negatively birefringent monosodium urate crystals. In practice, a classic clinical presentation in a patient with known gout and elevated uric acid is sufficient for presumptive treatment without aspiration.

Dr. Biernacki performs in-office joint aspiration when diagnostic clarification is needed — distinguishing gout from septic arthritis, pseudogout (calcium pyrophosphate crystals), and reactive arthritis.

Treating an Acute Attack

Three first-line options for acute gout management:

• NSAIDs (indomethacin, naproxen): Highest-dose NSAID therapy for 5–7 days — most effective when started within hours of attack onset
• Colchicine: Low-dose protocol (1.2mg followed by 0.6mg one hour later) is as effective as high-dose and significantly better tolerated; particularly effective in the first 12 hours
• Oral or injectable corticosteroids: For patients who cannot take NSAIDs or colchicine; triamcinolone intra-articular injection provides rapid dramatic relief

Long-Term Urate-Lowering Therapy — The Essential Next Step

The most important principle in gout management: treating only acute attacks without addressing the underlying hyperuricemia allows continued crystal deposition, progressive joint damage, and tophus formation. Urate-lowering therapy (allopurinol or febuxostat) targets a serum uric acid level below 6 mg/dL — the dissolution threshold for monosodium urate crystals. At this target, existing crystal deposits gradually dissolve and attack frequency progressively decreases. Most patients become gout-free within 12–24 months of achieving the uric acid target.

Dr. Biernacki coordinates with patients’ primary care physicians for long-term urate-lowering management while managing the podiatric complications of gout — joint damage, tophi, and associated foot deformity.

Your Board-Certified Podiatrists

Dr. Tom Biernacki, DPM

Board-Certified · FACFAS

Dr. Carl Jay, DPM

Board-Certified Podiatrist

Dr. Daria Gutkin, DPM

Podiatrist

Dr. Tom Biernacki, DPM

Affiliate Disclosure: This page contains affiliate links to products we recommend. If you purchase through these links, Balance Foot & Ankle may earn a small commission at no additional cost to you. We only recommend products we use with our patients.

Dr. Tom Biernacki, DPM is a double board-certified podiatrist and foot & ankle surgeon at Balance Foot & Ankle Specialists in Southeast Michigan. With over a decade of clinical experience, he specializes in heel pain, bunions, diabetic foot care, sports injuries, and minimally invasive surgery. Dr. Biernacki is a member of the APMA and ACFAS, and his patient education content on MichiganFootDoctors.com and YouTube has reached over one million views.